Back to top
more

Eagle Pharmaceuticals (EGRX)

(Delayed Data from OTC)

$0.65 USD

0.65
3,941

-0.05 (-7.17%)

Updated Nov 15, 2024 03:51 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (82 out of 250)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Nabriva (NBRV) Gains FDA Approval for Pneumonia Drug Xenleta

by Zacks Equity Research

The FDA approves Nabriva's (NBRV) new drug application for both intravenous and oral formulations of Xenleta to treat adult patients with community-acquired bacterial pneumonia.

Tirthankar Chakraborty headshot

New Strong Buy Stocks for August 14th

by Tirthankar Chakraborty

Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Wednesday

Eagle Pharmaceuticals (EGRX) Beats Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Eagle Pharmaceuticals (EGRX) delivered earnings and revenue surprises of 16.67% and 10.47%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Eagle Pharmaceuticals (EGRX) Q2 Earnings Expected to Decline

by Zacks Equity Research

Eagle Pharmaceuticals (EGRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Eagle Pharmaceuticals (EGRX) Beats Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Eagle Pharmaceuticals (EGRX) delivered earnings and revenue surprises of 77.19% and 12.43%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

Eagle Pharmaceuticals (EGRX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

by Zacks Equity Research

Eagle Pharmaceuticals (EGRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

New Strong Sell Stocks for April 22nd

by Zacks Equity Research

Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today.

Analysts Estimate Eagle Pharmaceuticals (EGRX) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Eagle Pharmaceuticals (EGRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Eagle Pharmaceuticals (EGRX) Q4 Earnings Expected to Decline

by Zacks Equity Research

Eagle Pharmaceuticals (EGRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Should Value Investors Buy Eagle Pharmaceuticals (EGRX) Stock?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Moving Average Crossover Alert: Eagle Pharmaceuticals (EGRX)

by Zacks Equity Research

Eagle Pharmaceuticals (EGRX) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front

Eagle Pharmaceuticals (EGRX) Q3 Earnings Match Estimates

by Zacks Equity Research

Eagle Pharmaceuticals (EGRX) delivered earnings and revenue surprises of 0.00% and 0.86%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

Baxter's Actifuse Flow Bone Graft Substitute Gets FDA Nod

by Zacks Equity Research

The latest FDA approval for Baxter's (BAX) Actifuse Flow bone graft is likely to boost its Advanced Surgery segment.

    Agios (AGIO) Assigns Ex-Celgene Executive to CEO Position

    by Zacks Equity Research

    Agios Pharmaceuticals (AGIO) names Dr. Jacqualyn Fouse as its next chief executive officer from Feb 1, 2019 onward.

      Eagle Pharmaceuticals (EGRX) Q2 Earnings and Revenues Top Estimates

      by Zacks Equity Research

      Eagle Pharmaceuticals (EGRX) delivered earnings and revenue surprises of 15.85% and 14.53%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

        Emergent (EBS) Q2 Earnings and Revenues Surpass Estimates

        by Zacks Equity Research

        Emergent Biosolutions (EBS) rides high on earnings as well as revenue beat in Q2.

          Pacira (PCRX) Q2 Earnings and Revenues Surpass Estimates

          by Zacks Equity Research

          Pacira (PCRX) encourages investors with better-than-expected earnings and revenues in Q2.

            Acorda (ACOR) Q2 Earnings and Revenues Surpass Estimates

            by Zacks Equity Research

            Acorda Therapeutics (ACOR) rides high on earnings as well as revenue beat in Q2.

              Agios (AGIO) Q2 Loss Narrows, Revenues Surpass Estimates

              by Zacks Equity Research

              Agios (AGIO) incurs narrower-than-expected loss in Q2. Additionally, higher license and collaboration/milestone fees lead to a significant year-over-year rise in revenues.

                Conatus' (CNAT) Q2 Loss Narrows, Revenues Lag Marginally

                by Zacks Equity Research

                Conatus (CNAT) incurs narrower-than-expected loss in Q2. Sales miss estimates.

                  NuVasive (NUVA) in Focus: Stock Moves 6.02% Higher

                  by Zacks Equity Research

                  NuVasive (NUVA) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

                    Is Eagle Pharmaceuticals (EGRX) Stock Outpacing Its Medical Peers This Year?

                    by Zacks Equity Research

                    Is (EGRX) Outperforming Other Medical Stocks This Year?

                      Agios (AGIO) Secures FDA Approval for Leukemia Drug Tibsovo

                      by Zacks Equity Research

                      Agios (AGIO) gains an FDA approval for its lead pipeline candidate, Tibsovo, for the treatment of relapsed/refractory acute myeloid leukemia (AML) in patients with an IDH1 mutation.

                        MedTech Overcomes Policy Hurdles, Long-Term Prospects Bright

                        by Zacks Equity Research

                        With the suspension of the controversial 2.3% medical device tax for another two years, the medical device industry is currently riding high on optimism.

                          New Strong Sell Stocks for May 2nd

                          by Zacks Equity Research

                          Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today: